PH12014502400A1 - Treatment method for steroid responsive dermatoses - Google Patents

Treatment method for steroid responsive dermatoses

Info

Publication number
PH12014502400A1
PH12014502400A1 PH12014502400A PH12014502400A PH12014502400A1 PH 12014502400 A1 PH12014502400 A1 PH 12014502400A1 PH 12014502400 A PH12014502400 A PH 12014502400A PH 12014502400 A PH12014502400 A PH 12014502400A PH 12014502400 A1 PH12014502400 A1 PH 12014502400A1
Authority
PH
Philippines
Prior art keywords
chloro
methyl
treatment method
steroid responsive
responsive dermatoses
Prior art date
Application number
PH12014502400A
Other languages
English (en)
Inventor
Agarwal Pankaj
Kumar Vinod
Xie Qing
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014502400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of PH12014502400A1 publication Critical patent/PH12014502400A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH12014502400A 2012-04-24 2014-10-24 Treatment method for steroid responsive dermatoses PH12014502400A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (1)

Publication Number Publication Date
PH12014502400A1 true PH12014502400A1 (en) 2015-01-12

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502400A PH12014502400A1 (en) 2012-04-24 2014-10-24 Treatment method for steroid responsive dermatoses

Country Status (26)

Country Link
US (2) US20150087683A1 (https=)
EP (1) EP2841053A1 (https=)
JP (1) JP2015514792A (https=)
KR (1) KR20150010943A (https=)
CN (1) CN104302275A (https=)
AR (1) AR090795A1 (https=)
AU (1) AU2013254849B2 (https=)
BR (1) BR112014026706A2 (https=)
CA (1) CA2873751A1 (https=)
CL (1) CL2014002861A1 (https=)
CO (1) CO7111283A2 (https=)
CR (1) CR20140491A (https=)
DO (1) DOP2014000238A (https=)
EA (1) EA201491914A1 (https=)
HK (1) HK1201726A1 (https=)
IL (1) IL235159A0 (https=)
MX (1) MX2014012904A (https=)
NZ (1) NZ628394A (https=)
PE (1) PE20142356A1 (https=)
PH (1) PH12014502400A1 (https=)
SG (1) SG11201406409VA (https=)
TW (1) TW201347758A (https=)
UA (1) UA113875C2 (https=)
UY (1) UY34762A (https=)
WO (1) WO2013160222A1 (https=)
ZA (1) ZA201407345B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E(IgE)介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
JP2013507382A (ja) * 2009-10-08 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
AR090795A1 (es) 2014-12-10
CL2014002861A1 (es) 2015-01-16
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
AU2013254849A1 (en) 2014-11-06
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26
TW201347758A (zh) 2013-12-01
CN104302275A (zh) 2015-01-21
CR20140491A (es) 2014-12-22
ZA201407345B (en) 2015-11-25
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
AU2013254849B2 (en) 2016-05-26
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
KR20150010943A (ko) 2015-01-29
CA2873751A1 (en) 2013-10-31
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
DOP2014000238A (es) 2014-12-15
IL235159A0 (en) 2014-12-31
WO2013160222A1 (en) 2013-10-31
UY34762A (es) 2013-11-29
JP2015514792A (ja) 2015-05-21
NZ628394A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA032955B3 (ru) Применение производного глутаримида для лечения эозинофильных заболеваний
UA114907C2 (uk) Гетероциклільні сполуки як інгібітори mek
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
PH12014502324A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
NZ708526A (en) Novel rock inhibitors
MX2013008074A (es) Combinacion.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201290603A1 (ru) Способ лечения
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
PH12014502400A1 (en) Treatment method for steroid responsive dermatoses
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.